Symbols

TRVI

Trevi Therapeutics·NASDAQ

--(--)

TRVI fundamentals

TRVI Q4 2025 Earnings

Trevi Therapeutics (TRVI) released its earnings on Mar 17, 2026: revenue was 0 (YoY --), met estimates; EPS was -0.06 (YoY +45.45%), beat estimates.

Revenue / YoY

EPS / YoY

-0.06

+45.45%

Report date

Mar 17, 2026

TRVI Earnings Call Summary for Q4,2025

Phase III Trial Milestones: Initiation of two pivotal trials in Q2 2026, targeting 300+ and 130 patients for IPF-related chronic cough.
Market Expansion: Addressing ~378,000 chronic cough patients across IPF and non-IPF ILD, with adaptive trial design for non-IPF ILD.
Financial Strength: $188M cash runway into 2028, supporting clinical execution without immediate capital needs.
FDA Alignment: Clear path for NDA submission with Phase III data, including safety and efficacy endpoints.

Earnings

EPS

Revenue

Revenue & Expenses

Key Indicators

Trevi Therapeutics (TRVI) key financial stats and ratios, covering profitability, financial health, and leverage.

Income Statement

Trevi Therapeutics (TRVI)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.

Trend

Breakdown

Balance Sheet

Trevi Therapeutics (TRVI)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.

Trend

Breakdown

Cash Flow

Trevi Therapeutics (TRVI)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.

Trend

Breakdown